Pramlintide (Symlin)
Pramlintide acetate
Pramlintide (brand name Symlin) is a synthetic analog of human amylin, an FDA-approved injectable peptide used as adjunctive therapy to mealtime insulin in type 1 and type 2 diabetes to improve postprandial glycemic control.
Last updated: 2026-03-13
Safety Summary
Gastrointestinal adverse effects (nausea, vomiting) are the most common and are typically dose-dependent and transient, resolving with continued use and gradual titration. Nausea occurs in 30-50% of patients during initiation. The most clinically significant risk is severe hypoglycemia when used with insulin (FDA Boxed Warning), occurring primarily within the first 3 hours post-injection. This risk is managed by mandatory 50% reduction in mealtime insulin dose upon initiation and frequent blood glucose monitoring. Long-term safety studies up to 2 years show no organ toxicity, no cancer risk signals, no tolerance development, and no withdrawal effects. Cardiovascular safety analyses show no increased MACE risk. No consistent differences by gender, race, or age, PMC5630431, PMC2975690.
Known Side Effects
48% in T1D (vs 17% placebo); 28% in T2D (vs 12% placebo)
T1D: patient-ascertained incidence 16.8% (0-3 months) vs 10.8% placebo; T2D: 8.2% vs 2.1% placebo (0-3 months). Rates decline during maintenance phase.
17% in T1D (vs 2% placebo); 9% in T2D (vs 2% placebo)
11% in T1D (vs 7% placebo); 8% in T2D (vs 4% placebo)
13% in T2D (vs 7% placebo)
8% in T2D (vs 7% placebo)
7% in both T1D and T2D (vs 4% placebo)
5-6% (vs 4% placebo)
7% in T1D (vs 5% placebo)
Reported in post-marketing; erythema, edema, pruritus at injection site
Rare (post-marketing reports only)
14% in T1D (vs 10% placebo)
Who Should NOT Use This
FDA label Section 4 contraindication.
Patients who cannot recognize hypoglycemic symptoms are at high risk of severe hypoglycemia with pramlintide+insulin. FDA label Section 4.
Pramlintide slows gastric emptying and would worsen gastroparesis. FDA label Section 4.
Must never be mixed with insulin in the same syringe -- alters pharmacokinetics of both products. Administer as separate injections. FDA label Section 5.4.
Patients with poor glycemic control should not initiate pramlintide per FDA label Section 5.1 patient selection criteria.
Pramlintide affects GI motility; combining with other GI motility agents is contraindicated. FDA label Section 5.6 and 7.3.
Safety and effectiveness not established in pediatric patients. FDA label Section 8.4.
Low potential to cross placental barrier, but congenital abnormalities observed in rat studies at 10x human dose. Insufficient human data. FDA label Section 8.1.
Talk to Your Doctor
Before considering Pramlintide (Symlin), discuss it with your healthcare provider. Ask about potential interactions with your current medications, whether it is appropriate for your health conditions, and what monitoring may be needed.
Sources: [1-15]
Evidence Assessment
Pramlintide is an FDA-approved medication (Symlin, original approval March 16, 2005, NDA 021332) supported by numerous large-scale Phase 3 randomized controlled trials (>5000 patients exposed across the clinical program), systematic reviews and meta-analyses, and extensive post-marketing surveillance for the management of type 1 and type 2 diabetes.
1A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetesPMID 11919132
Whitehouse F, et al. - Diabetes Care (2002) - RCT with open-label extension - 480
Pramlintide significantly reduced HbA1c and body weight over 52 weeks compared to placebo in Type 1 diabetics. Nausea was the most common adverse event.
Limitations: High dropout rate largely due to nausea.
2Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass SurgeryNCT01841359
Joslin Diabetes Center - ClinicalTrials.gov - Phase 4, open-label, proof-of-concept - 22
Investigating pramlintide for post-bariatric hypoglycemia. Study completed but detailed numeric outcomes not posted on registry.
Limitations: Small sample, non-randomized, results not publicly available.
3Safety of pramlintide initiation in usual clinical care (observational study)PMID 20518811
(2010) - Phase 4, open-label, multicenter, observational safety study - 1297
During titration (0-3 months): severe hypoglycemia incidence 4.8% in T1DM and 2.8% in T2DM; event rates 0.33 and 0.19 events/patient-year. Incidence declined during maintenance (>3-6 months).
Limitations: Open-label observational design; no 95% CIs reported.
4Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation studyPMID 17504894
Aronne et al. - J Clin Endocrinol Metab (2007) - Phase II, randomized, double-blind, placebo-controlled, dose-escalation - 204
Pramlintide up to 240 mcg TID: placebo-corrected weight reduction ~3.7% +/- 0.5% (~3.6 +/- 0.6 kg; P<0.001); waist circumference reduction ~3.6 +/- 1.1 cm; 31% achieved >=5% weight loss vs 2% placebo (P<0.001).
Limitations: Short duration (16 weeks), no long-term follow-up, 95% CIs not reported in abstract.
5Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis
- Oncotarget (2017) - Systematic review and meta-analysis (10 RCTs in T1D) - ~3300 (T1D across included trials)
HbA1c reduction: -0.39% (95% CI -0.56 to -0.22). Weight loss: -1.5 to -3 kg. Nausea 30-50%, dropout 20-30%. Increased severe hypoglycemia risk.
Limitations: Mostly short-term studies (<=52 weeks), industry-sponsored, heterogeneous doses/durations, high GI AE rates.
6Efficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes Mellitus
(2010) - Systematic review - >5000 exposed across reviewed trials
T2D meta-analysis: HbA1c -0.33% (95% CI -0.51 to -0.14), weight -2.6 kg (95% CI -3.4 to -1.7). Consistent modest benefits across T1D and T2D.
Limitations: No long-term outcome data (MACE, mortality). Publication bias risk. Inconsistent CI reporting.
7Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial
Hollander PA, Levy P, Fineman MS, Maggs DG, et al. - Diabetes Care (2003) - Phase III, randomized, double-blind, placebo-controlled - 656
Pramlintide 120 mcg BID + insulin vs placebo + insulin over 52 weeks: HbA1c -0.62% vs -0.25% (p<0.05); weight -1.9 kg vs +0.7 kg placebo. 46% vs 28% achieved HbA1c <8% (p<0.05).
Limitations: Industry-sponsored (Amylin Pharmaceuticals), fixed-dose without individualization, significant nausea leading to dropouts.
8Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
Ryan GJ, et al. (2009) - Narrative review - N/A (review of Phase III program)
Across Phase III programs pramlintide reduced 2-hour postprandial glucose by ~3.4-5 mmol/L and HbA1c by ~0.2-0.7% vs placebo; modest weight loss (~0.5-1.6 kg). Transient nausea and increased severe hypoglycemia risk when not reducing insulin doses.
Limitations: Narrative review, not systematic.
9Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk
- Vasc Health Risk Manag (2008) - Comprehensive review - N/A
Comprehensive overview of pramlintide pharmacology, PK (half-life ~48 min, SC bioavailability 30-40%, Tmax ~20 min), mechanism of action, clinical efficacy data, and cardiovascular biomarker effects.
Limitations: Review article, not primary data.
10The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysisPMID 21199269
Singh-Franco D, Perez A, Harrington C (2011) - Systematic review and meta-analysis - Multiple T2D and obesity trials
Confirmed modest HbA1c reduction and weight loss in T2D; weight loss in obesity trials 3-4 kg vs placebo over 16-24 weeks.
Limitations: Off-label obesity evidence is low-moderate quality; not pursued to approval.
11Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development
Bower RL, Hay DL - Br J Pharmacol (2016) - Mechanistic review - N/A
Detailed characterization of pramlintide's receptor binding profile (AMY1/AMY2/AMY3/CTR), structure-activity relationships of proline substitutions preventing aggregation, and comparison to endogenous amylin.
Limitations: Review article; receptor potency data from heterologous expression systems.
12Study Reanalysis Using a Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Pramlintide in Subjects with Type 1 Diabetes
(2012) - PK/PD modeling study - N/A (model-based)
PK parameters: volume of distribution Vc 19.1 L, Vss ~33-51 L (IV T1DM), clearance 0.955 L/min. Confirms ~48 min half-life.
Limitations: Model-based reanalysis, not a clinical endpoint trial.
13Closed-loop insulin+pramlintide delivery studyNCT06422325
- ClinicalTrials.gov - Crossover closed-loop device study - Not posted
Comparing insulin-only vs insulin+pramlintide in closed-loop system. No results posted.
Limitations: No posted results.
14Automated dual-hormone artificial pancreas with pramlintide and insulinNCT04243629
- ClinicalTrials.gov - Pilot/feasibility study - Not posted
Investigating co-administration of pramlintide and insulin via automated device over 4 weeks. No results posted.
Limitations: No posted results.
15Effect of Adjunctive Pramlintide Treatment on Treatment Satisfaction in Patients With Type 1 Diabetes
Marrero et al. - Diabetes Care (2007) - Phase III, randomized, placebo-controlled (patient-reported outcomes) - Not reported in abstract
Improved treatment satisfaction with pramlintide vs placebo despite modest HbA1c effects.
Limitations: Numeric effect sizes and 95% CIs not in public abstract.